A Phase 2, Open-label, Dose-escalation Study to Evaluate the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects with Pulmonary Arterial Hypertension (PAH)

Investigator: Sandeep Sahay

Study Coordinator: Rosa Barrosa da Costa

Status: Enrolling

ClinicalTrials.gov Number: NCT04266197

Phone: 713.441.5660

Protocol Number: PRO00038153

Description

The purpose of this study is to investigate acute changes in exercise capacity and exertional symptoms (i.e., dyspnea) post dosing of RT234, as assessed by a cardiopulmonary exercise test (CPET), and 6 -minute walk test (6MWT). In addition, acute changes in severity of PAH symptoms before and after CPET and 6MWT will be assessed.
More to Explore
Search Clinical Trials
Join a Clinical Trial
Clinical Research Support Services for Investigators
Weill Cornell Medical College Clinical Trials